Targeting Platform - ‘OptiLinked’ FDCs

Solid tumours require therapies that can penetrate rapidly and completely. ADCs need to be cleared from normal tissues quickly. With its revolutionary OptiLink^TM technology platform, Antikor has adopted an altogether more novel approach for ADCs using much smaller antibody fragments (single-chain scFvs) that are relatively easy to discover and can be bioengineered with a high number of surface lysine residues for multiple drug-molecule conjugation via their -NH2 side-chains. Quite counter-intuitively, this provides far higher payloads loadings on a small fragment than have so far been achieved with whole MAbs, without running the risk of product manufacturing or stability problems.

References

1. Deonarain MP, Yahioglu G, Stamati I, Marklew J. Emerging formats for next-generation antibody drug conjugates. Expert Opin Drug Discov. 2015 May;10(5):463-81. doi: 10.1517/17460441.2015.1025049
 

 

 

 

 

 

 

 

 

 

OptiLinked-FDC platform advantages:-

• Maximisation of drug potency by facilitating higher drug-loading ratios for targeted delivery of many active drug molecules
• Small format to enable fast and even tumour penetration ensuring more rapid efficacy
• Small format and lack of Fc to facilitate fast clearance from normal tissue and circulation
• Prevention of unwanted molecular interactions that inhibit drug activity
• Applicable to most antibody fragment formats, improving their versatility for a 3rd party
• Ability to reverse engineer whole MAb and ADCs to make next-generation FDC versions
• Improved drug-conjugate manufacturing, solubility and formulation
• Preserved scFv stability and binding functions
• Improved pharmacokinetics/dynamics over whole MAbs